Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Low dose naltrexone therapy in multiple sclerosis.

Y P Agrawal1

  • 1Department of Pathology, The University of Iowa Roy J. and Lucille A. Carver College of Medicine, Room 153 B MRC, 200 Hawkins Drive, Iowa City, IA 52242-1182, USA. yashpal-agrawal@uiowa.edu

Medical Hypotheses
|February 8, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Possible importance of antibiotics and naltrexone in neurodegenerative disease.

European journal of neurology·2006
Same author

The vWF content of factor VIII concentrates.

Transfusion·2001
Same author

Complement and anti-alpha-galactosyl natural antibody-mediated inactivation of murine retrovirus occurs in adult serum but not in umbilical cord serum.

Gene therapy·1999
Same author

Interaction of vesicular stomatitis virus-G pseudotyped retrovirus with CD34+ and CD34+ CD38- hematopoietic progenitor cells.

Gene therapy·1998
Same author

A placebo-controlled flow cytometric study of the effect of low-dose prednisolone treatment on sperm-bound antibody levels.

International journal of andrology·1996
Same author

Cell-cycle kinetics and VSV-G pseudotyped retrovirus-mediated gene transfer in blood-derived CD34+ cells.

Experimental hematology·1996

Low-dose naltrexone shows promise for multiple sclerosis (MS) treatment, potentially preventing relapses and slowing disease progression. Research suggests it protects oligodendrocytes by reducing nitric oxide synthase activity and glutamate excitotoxicity.

Area of Science:

  • Neuroimmunology
  • Pharmacology

Background:

  • Multiple sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system.
  • Patients report anecdotal benefits from low-dose naltrexone (LDN) for MS management.
  • Current MS treatments have limitations, necessitating exploration of novel therapeutic avenues.

Purpose of the Study:

  • To explore the proposed mechanism of action for low-dose naltrexone in multiple sclerosis.
  • To investigate how LDN may prevent oligodendrocyte apoptosis and reduce neurotoxicity.

Main Methods:

  • The study proposes a biochemical pathway for LDN's effects.
  • It focuses on the roles of inducible nitric oxide synthase (iNOS), peroxynitrite, and glutamate excitotoxicity.

Main Results:

Related Experiment Videos

  • LDN is proposed to reduce iNOS activity, decreasing peroxynitrite formation.
  • This mechanism may prevent inhibition of glutamate transporters.
  • Prevention of glutamate excitotoxicity could protect neuronal cells and oligodendrocytes.

Conclusions:

  • Low-dose naltrexone may offer a neuroprotective effect in multiple sclerosis.
  • Further clinical trials are crucial to validate these proposed mechanisms and patient-reported benefits.
  • Investigating LDN aligns with addressing patient needs in MS treatment.